The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already approved. Both versions will launch in July 2023. Last week, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback